文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

非重症COVID-19患者接受治疗性肝素抗凝

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
PubMed 文献 · N Engl J Med · 2021-08-04
一句话结论非重症COVID-19住院患者,初始治疗性肝素抗凝较常规药物血栓预防提高无器官支持存活至出院的概率。

该开放标签、适应性、多平台随机对照试验纳入2219例非重症COVID-19住院患者(入组时无重症监护级别器官支持),比较治疗性肝素抗凝与常规药物血栓预防。主要终点为无器官支持天数(将院内死亡赋值为-1,合并至第21天无心血管或呼吸器官支持天数)。治疗性抗凝增加无器官支持天数的概率为98.6%(调整OR 1.27,95%可信区间1.03-1.58),无器官支持存活至出院率的调整绝对组间差异为4.0个百分点(95%可信区间0.5-7.2)。大出血在治疗性抗凝组为1.9%,血栓预防组为0.9%。

要点

  • 非重症COVID-19住院患者(入组时无重症监护级别器官支持)初始治疗性肝素抗凝较常规血栓预防增加无器官支持天数(调整OR 1.27,95%可信区间1.03-1.58)。
  • 无器官支持存活至出院的调整绝对组间差异为4.0个百分点(95%可信区间0.5-7.2),支持治疗性抗凝。
  • D-二聚体高水平队列治疗性抗凝优效概率97.3%,低水平队列92.9%,未知队列97.3%。
  • 大出血发生率治疗性抗凝组1.9%,常规血栓预防组0.9%。
  • 试验因预设优效性标准达到而提前停止。

适用人群与场景

  • 住院的COVID-19患者,且非重症(定义为入组时无重症监护级别器官支持)。

诊断标准与关键阈值

  • 非重症定义:入组时无重症监护级别器官支持。
  • 主要终点无器官支持天数:将院内死亡赋值为-1,合并至第21天无心血管或呼吸器官支持天数(针对存活至出院患者)。
  • 按基线D-二聚体水平评估:高水平队列、低水平队列、未知水平队列。

处置流程与药物剂量

  • 第一步:对非重症COVID-19住院患者(无重症监护级别器官支持),考虑初始治疗性肝素抗凝策略。
  • 第二步:治疗性肝素抗凝方案为实用性定义方案(原文未提供具体剂量、途径、频次或目标值)。
  • 第三步:对照为常规药物血栓预防(原文未提供具体药物、剂量或方案)。
  • 第四步:监测大出血(治疗性抗凝组发生率1.9%,常规血栓预防组0.9%)。

红旗征与不能漏的情况

  • 大出血:治疗性抗凝组发生率1.9%,常规血栓预防组0.9%,需监测。

研究设计与关键结果

  • 研究类型:开放标签、适应性、多平台随机对照试验;最终分析2219例患者。
  • 人群:住院COVID-19非重症患者(入组时无重症监护级别器官支持)。
  • 干预与对照:治疗性肝素抗凝 vs 常规药物血栓预防。
  • 主要终点:治疗性抗凝增加无器官支持天数的概率98.6%(调整OR 1.27,95%可信区间1.03-1.58)。
  • 次要终点:无器官支持存活至出院的调整绝对组间差异4.0个百分点(95%可信区间0.5-7.2),支持治疗性抗凝。
  • 亚组:治疗性抗凝优效概率在高D-二聚体队列97.3%,低D-二聚体队列92.9%,未知D-二聚体队列97.3%。
  • 不良事件:大出血治疗性抗凝组1.9%,常规血栓预防组0.9%。

证据类型、等级与局限

  • 证据类型:开放标签、适应性、多平台随机对照试验。
  • 试验因预设优效性标准达到而提前停止。
  • 局限:开放标签设计;原文未报告其他局限。

对床旁实践的改变

  • 对于非重症COVID-19住院患者(入组时无重症监护级别器官支持),初始治疗性肝素抗凝可提高无器官支持存活至出院的概率。
  • 需权衡大出血风险:治疗性抗凝组大出血1.9% vs 常规血栓预防0.9%。
  • 原文未提供具体肝素剂量、给药途径、频次或目标值,临床实施需参考原文方案或当地指南。
  • 不适用于重症COVID-19患者(需重症监护级别器官支持者),原文未纳入该人群。

指南或共识出处

  • ATTACC、ACTIV-4a和REMAP-CAP试验(ClinicalTrials.gov NCT04372589、NCT04505774、NCT04359277、NCT02735707)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.

METHODS: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.

RESULTS: The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.

CONCLUSIONS: In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021. PMID: 34351721. doi:10.1056/NEJMoa2105911

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。